Enlivex Secures Australian Patent Protection Until 2040
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 15 2026
0mins
Enlivex announced the issuance of an Australian patent. The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra to treat subjects with osteoarthritis. With this issuance, the company has secured patent protection for Allocetra in osteoarthritis in an additional major jurisdiction, further strengthening its global intellectual property position as the Phase 2b clinical program for Allocetra advances. Enlivex recently reported the dosing of the first patient at a U.S. clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. The Phase 2b follows Enlivex's previous announcement regarding three-month and six-month topline data from the Phase 2b stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial that evaluated Allocetra in patients with moderate-to-severe knee OA.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENLV
Wall Street analysts forecast ENLV stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.581
Low
13.00
Averages
13.00
High
13.00
Current: 0.581
Low
13.00
Averages
13.00
High
13.00
About ENLV
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enlivex Faces Nasdaq Compliance Risk with Share Price Below $1
- Compliance Notification: Enlivex was notified by Nasdaq that its share price has remained below the $1 minimum bid requirement for 30 consecutive business days, posing a compliance risk that could affect investor confidence and market performance.
- Restoration Deadline: The company has until November 9, 2026, to regain compliance, and if it fails to meet this deadline, it may qualify for an additional 180-day extension, increasing future uncertainty.
- Reverse Stock Split Possibility: To secure the second compliance period, Enlivex may need to implement a reverse stock split and meet other Nasdaq Capital Market listing standards, which could impact shareholder structure and market liquidity.
- Market Reaction: The notification of compliance risk may lead to a decline in investor confidence in Enlivex, potentially affecting its stock performance, especially in the context of fierce competition in the biopharmaceutical industry.
See More
Enlivex's RAIN Token Listed on HTX Exchange
- Market Access Enhancement: Enlivex's RAIN token was listed on the HTX exchange on April 29, 2026, significantly increasing its global market access and liquidity, which is expected to attract more investor interest.
- Exchange Background: HTX is one of the leading global cryptocurrency exchanges, with an annual trading volume of approximately $3.3 trillion in 2025 and over 59 million users, showcasing its strong market influence and active trading environment.
- Asset Holdings: As of April 27, 2026, Enlivex's holdings of RAIN tokens have increased to approximately 78.8 billion, with a total value of $567 million, indicating the company's strategic positioning in the digital asset space is yielding results.
- Governance and Utility: The RAIN token serves as the governance and utility token for a decentralized prediction markets protocol, enabling users to create and trade markets tied to real-world events, further enhancing Enlivex's competitiveness in the emerging market.
See More
Enlivex Expands RAIN Holdings, Strengthening Treasury Strategy
- Increased RAIN Holdings: As of April 27, 2026, Enlivex's total RAIN token holdings rose to 78,819,756,062 tokens, valued at $567 million, indicating strong performance in the prediction markets and potential for additional shareholder value creation.
- Acquisition Strategy Advantage: Enlivex secured RAIN tokens by partially exercising its option at a price of $0.0033 per token, representing approximately a 55% discount to RAIN's closing price on April 27, 2026, showcasing the company's disciplined financial strategy amid market volatility.
- Growing Market Demand: CEO Oren Hershkovitz highlighted increasing institutional interest in prediction markets, suggesting that the company's strategic positioning in this emerging field could lead to long-term business growth opportunities.
- Future Outlook: Enlivex's digital asset treasury strategy, combined with its clinical-stage immunotherapy Allocetra™, aims to drive the company's development in treating age-related diseases while capitalizing on the evolving prediction markets ecosystem.
See More
Enlivex Secures Danish Clinical Trial Approval for Allocetra™
- Clinical Trial Approval: Enlivex Ltd. has received approval from the Danish Medicines Agency to enroll patients for the Phase 2b trial of Allocetra™, marking a significant advancement in the company's global strategy.
- FDA Clearance Follow-Up: This approval follows the recent FDA clearance for the trial in the U.S., highlighting Allocetra™'s potential in treating moderate-to-severe knee osteoarthritis, which currently affects over 32 million Americans.
- Multicenter Trial Design: The trial will be conducted across multiple clinical centers in the U.S., Denmark, and Poland, aiming to evaluate the efficacy and safety of Allocetra™, particularly focusing on key endpoints related to pain relief and functional improvement.
- Strong Market Demand: Given the high prevalence of knee osteoarthritis worldwide, projected to impact 78 million Americans by 2040, Enlivex's research is set to provide much-needed treatment options in this area, presenting significant market potential.
See More
Enlivex Launches ENLVon Tokenized Shares on Ondo
- Tokenized Stock Launch: Enlivex Ltd. has launched ENLVon on the Ondo Global Markets platform, enabling non-U.S. retail and institutional investors to gain direct exposure to its ordinary shares through digital infrastructure, marking a significant innovation at the intersection of capital markets and blockchain.
- Market Share Leadership: Ondo has established itself as a leader in the tokenized stock market with over 61% market share, supporting approximately 265 tokenized securities and ETFs, showcasing its strong influence and growth potential in this emerging asset class.
- Lower Investment Barriers: The ENLVon model allows for fractional investments with low minimum amounts and near-instant settlement, thereby broadening accessibility for a global base of digitally native investors and facilitating wider access to traditional securities.
- Strategic Implications: Enlivex CEO Oren Hershkovitz emphasized that the launch of ENLVon not only enhances market visibility but also has the potential to attract more investors by increasing liquidity and trading flexibility, further advancing the company's clinical-stage immunotherapy development.
See More
Rain Foundation Launches $5 Million Grant Program for Prediction Markets
- Grant Program Launch: The Rain Foundation has announced a $5 million grant program aimed at supporting developers and creators worldwide in building, launching, and monetizing independent prediction markets through AI agents, which is expected to accelerate market innovation and drive industry growth.
- AI Agent Interface Release: The Rain Foundation has launched an AI agent-ready interface that allows developers using OpenClaw and other AI agents to generate live prediction markets via a single prompt, significantly lowering the technical barriers to market development and attracting more creative ideas into the market.
- Market Access Expansion: As interest in prediction markets continues to grow, the Rain Foundation is opening its protocol system to a broader group of developers, providing the necessary infrastructure for them to create and launch their own applications and prediction markets directly on the protocol, which is anticipated to enhance market activity.
- RAIN Token Potential: Enlivex CEO Oren Hershkovitz stated that the success of the Rain protocol will contribute to the value growth of the RAIN token, as approximately 2.5% of the total trading volume is expected to be allocated for automatic buy-and-burn of the RAIN token, thereby enhancing its scarcity and market appeal.
See More
Enlivex Faces Nasdaq Compliance Risk with Share Price Below $1
- Compliance Notification: Enlivex was notified by Nasdaq that its share price has remained below the $1 minimum bid requirement for 30 consecutive business days, posing a compliance risk that could affect investor confidence and market performance.
- Restoration Deadline: The company has until November 9, 2026, to regain compliance, and if it fails to meet this deadline, it may qualify for an additional 180-day extension, increasing future uncertainty.
- Reverse Stock Split Possibility: To secure the second compliance period, Enlivex may need to implement a reverse stock split and meet other Nasdaq Capital Market listing standards, which could impact shareholder structure and market liquidity.
- Market Reaction: The notification of compliance risk may lead to a decline in investor confidence in Enlivex, potentially affecting its stock performance, especially in the context of fierce competition in the biopharmaceutical industry.
See More
Enlivex's RAIN Token Listed on HTX Exchange
- Market Access Enhancement: Enlivex's RAIN token was listed on the HTX exchange on April 29, 2026, significantly increasing its global market access and liquidity, which is expected to attract more investor interest.
- Exchange Background: HTX is one of the leading global cryptocurrency exchanges, with an annual trading volume of approximately $3.3 trillion in 2025 and over 59 million users, showcasing its strong market influence and active trading environment.
- Asset Holdings: As of April 27, 2026, Enlivex's holdings of RAIN tokens have increased to approximately 78.8 billion, with a total value of $567 million, indicating the company's strategic positioning in the digital asset space is yielding results.
- Governance and Utility: The RAIN token serves as the governance and utility token for a decentralized prediction markets protocol, enabling users to create and trade markets tied to real-world events, further enhancing Enlivex's competitiveness in the emerging market.
See More
Enlivex Expands RAIN Holdings, Strengthening Treasury Strategy
- Increased RAIN Holdings: As of April 27, 2026, Enlivex's total RAIN token holdings rose to 78,819,756,062 tokens, valued at $567 million, indicating strong performance in the prediction markets and potential for additional shareholder value creation.
- Acquisition Strategy Advantage: Enlivex secured RAIN tokens by partially exercising its option at a price of $0.0033 per token, representing approximately a 55% discount to RAIN's closing price on April 27, 2026, showcasing the company's disciplined financial strategy amid market volatility.
- Growing Market Demand: CEO Oren Hershkovitz highlighted increasing institutional interest in prediction markets, suggesting that the company's strategic positioning in this emerging field could lead to long-term business growth opportunities.
- Future Outlook: Enlivex's digital asset treasury strategy, combined with its clinical-stage immunotherapy Allocetra™, aims to drive the company's development in treating age-related diseases while capitalizing on the evolving prediction markets ecosystem.
See More
Enlivex Secures Danish Clinical Trial Approval for Allocetra™
- Clinical Trial Approval: Enlivex Ltd. has received approval from the Danish Medicines Agency to enroll patients for the Phase 2b trial of Allocetra™, marking a significant advancement in the company's global strategy.
- FDA Clearance Follow-Up: This approval follows the recent FDA clearance for the trial in the U.S., highlighting Allocetra™'s potential in treating moderate-to-severe knee osteoarthritis, which currently affects over 32 million Americans.
- Multicenter Trial Design: The trial will be conducted across multiple clinical centers in the U.S., Denmark, and Poland, aiming to evaluate the efficacy and safety of Allocetra™, particularly focusing on key endpoints related to pain relief and functional improvement.
- Strong Market Demand: Given the high prevalence of knee osteoarthritis worldwide, projected to impact 78 million Americans by 2040, Enlivex's research is set to provide much-needed treatment options in this area, presenting significant market potential.
See More
Enlivex Launches ENLVon Tokenized Shares on Ondo
- Tokenized Stock Launch: Enlivex Ltd. has launched ENLVon on the Ondo Global Markets platform, enabling non-U.S. retail and institutional investors to gain direct exposure to its ordinary shares through digital infrastructure, marking a significant innovation at the intersection of capital markets and blockchain.
- Market Share Leadership: Ondo has established itself as a leader in the tokenized stock market with over 61% market share, supporting approximately 265 tokenized securities and ETFs, showcasing its strong influence and growth potential in this emerging asset class.
- Lower Investment Barriers: The ENLVon model allows for fractional investments with low minimum amounts and near-instant settlement, thereby broadening accessibility for a global base of digitally native investors and facilitating wider access to traditional securities.
- Strategic Implications: Enlivex CEO Oren Hershkovitz emphasized that the launch of ENLVon not only enhances market visibility but also has the potential to attract more investors by increasing liquidity and trading flexibility, further advancing the company's clinical-stage immunotherapy development.
See More
Rain Foundation Launches $5 Million Grant Program for Prediction Markets
- Grant Program Launch: The Rain Foundation has announced a $5 million grant program aimed at supporting developers and creators worldwide in building, launching, and monetizing independent prediction markets through AI agents, which is expected to accelerate market innovation and drive industry growth.
- AI Agent Interface Release: The Rain Foundation has launched an AI agent-ready interface that allows developers using OpenClaw and other AI agents to generate live prediction markets via a single prompt, significantly lowering the technical barriers to market development and attracting more creative ideas into the market.
- Market Access Expansion: As interest in prediction markets continues to grow, the Rain Foundation is opening its protocol system to a broader group of developers, providing the necessary infrastructure for them to create and launch their own applications and prediction markets directly on the protocol, which is anticipated to enhance market activity.
- RAIN Token Potential: Enlivex CEO Oren Hershkovitz stated that the success of the Rain protocol will contribute to the value growth of the RAIN token, as approximately 2.5% of the total trading volume is expected to be allocated for automatic buy-and-burn of the RAIN token, thereby enhancing its scarcity and market appeal.
See More
